Objective To investigate the hemocompatibility of the acellular valved bovine jugular vein conduit (BJVC) treated with polyepoxy compound (PC), and discuss its application in cardiovascular surgery and tissue engineering in the future. Methods BJVC treated with PC was regarded as the experiment group and BJVC treated with glutaraldehyde (GA) was considered to be the control group. Rat blood was used for in vitro hemolytic test to calculate hemolytic rates of BJVC, and curve of absorbanceclotting time was drawn. Human blood was used to determine the level of D-dimeride and complement activation C3a des Arg, and test its hemocompatibility in vitro. We divided 20 canines into the experiment group (PC group, n=10) and the control group (GA group, n=10) by random digital table. The BJVC treated with PC or GA were implanted between the pulmonary artery and right ventricle. Ten months after the implantation, thrombus and histological observation were performed to evaluate the blood compatibility in vivo. Results The hemolytic rate in the PC group (0.23%) was lower than that in the GA group (0.35%), which was in accordance with the national standard of hemolytic test (lt;5%). The curve of absorbanceclotting time in the experiment group declined more slowly than that of the control group. The D-dimeride level in the experiment group was significantly lower than that of the control group (0.10±0.01 μg/ml vs. 0.12±0.02 μg/ml , t=3.277, P=0.004), but both of them were within the normal level. The level of complement C3a des Arg in the experiment group was significantly lower than that of the control group (0.74±0.09 μg/ml vs. 1.02±0.19 μg/ml, t=4.183, P=0.001). Eight canines survived 10 months after the implantation in both the two groups, and two other canines in each group died due to ventricular fibrillation. Three canines were discovered to have thrombus in the control group while no thrombus was observed in the experiment group. Conclusion Compared with GA, acellular BJVC treated with PC has superiority in hemocompatibility in vitro and vivo, and has potential application in clinical research and practice.
ObjectiveTo understand the relationship between obesity, hyperglycemia, hypertension, and lipid metabolism disorder in metabolic syndrome and hepatocellular carcinoma (HCC), and to provide reference for screening, diagnosis, treatment, and prevention of HCC in clinic.MethodThe related literatures about the relationship between metabolic syndrome related factors (obesity, hyperglycemia, hypertension, and lipid metabolism disorder) and HCC were searched and summarized.ResultsObesity, hyperglycemia, hypertension, and abnormal lipid metabolism in metabolic syndrome were closely related to HCC, which were the high risk factors for leading to HCC, indicating that metabolic syndrome was closely related to the risk of HCC.ConclusionsMetabolic syndrome is closely related to the risk of HCC. It is of great significance for screening, diagnosis, treatment, and prevention of HCC to deeply understand the mechanism and determinants of HCC caused by metabolic syndrome.